NCT07593092RecruitingPhase 1
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
A Phase 1 Trial, Evaluating the Safety and Tolerability of XmAb541 in Combination With XmAb808 in Advanced Solid Tumors
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on participants' tumor outcomes.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 11 May 2026
- Start date
- 30 Jun 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Xencor, Inc.
- Diseases
- Ovarian cancer
- NCT number
- NCT07593092
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 90
- From 30 Jun 2026 to the primary completion date, Dec 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior exposure to a CLDN6 targeting immune cell engager
- Have any condition requiring systemic treatment with corticosteroids, prednisone equivalents, or other immunosuppressive medications within 14 days prior to first dose of study drug
Other illness
- Active known or suspected autoimmune disease
- Clinically significant cardiovascular, pulmonary or gastrointestinal disease
- Active viral hepatitis B or hepatitis C
Other
- Patients with treated brain metastases may participate, provided they are radiologically stable.
Who the study is looking for
- Age ≥ 18 years.
- CLDN6+ tumor
- Histological or cytological documentation of locally advanced, recurrent, or metastatic high grade serous ovarian carcinoma (HGSOC) including fallopian tube or primary peritoneal origin
- Adequate Eastern Cooperative Oncology Group performance status
- Life expectancy ≥ 3 months
- Adequate organ function
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Fort Worth | United States | Recruiting |
| - Coordinator of this site? Confirm its status | Lake Success | United States | Recruiting |
| - Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| - Coordinator of this site? Confirm its status | The Bronx | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.